Revolution Medicines, INC Form 4 insider transactions

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,599 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Revolution Medicines' Chief Financial Officer, Jack Anders, sold 2,635 shares of common stock to cover tax obligations related to vested restricted stock units.

Director Thilo Schroeder indirectly acquired shares of Revolution Medicines through investment funds he manages, while disclaiming beneficial ownership except for pecuniary interest.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,554 shares of common stock at an average price of $55.1337, as part of a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock and exercised stock options under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on October 31, 2024, under a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold 50,000 shares of common stock on October 11, 2024, according to a recent SEC filing.

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold 30,000 shares of common stock at an average price of $50.3591 per share on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Revolution Medicines, Jack Anders, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Barbara Weber of Revolution Medicines, Inc. executed a sale of common stock on October 8, 2024, under a pre-arranged 10b5-1 trading plan.

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Jack Anders, CFO of Revolution Medicines, sold 2,244 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,715 shares of common stock on September 16, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,331 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,665 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,454 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock on September 13, 2024, under a pre-arranged 10b5-1 trading plan.

Director Barbara Weber of Revolution Medicines, Inc. reports selling 1,808 shares of common stock on August 21, 2024.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 16,667 shares of common stock at an average price of $42.9825, while also exercising options to acquire the same number of shares at $4.09.

Frank Clyburn, a director at Revolution Medicines, acquired shares and options in the company on August 5, 2024.

Mark A. Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Mark Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, sold 2,399 shares of common stock at $40.83 per share on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Elizabeth M. Anderson, a director of Revolution Medicines, Inc., files an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.